FDA OKs 2nd gene therapy for blood cancer; 1st for adults

Wikimedia Commons photo credit Blogotron

TRENTON, N.J. (AP) – U.S. regulators have approved a second gene therapy for blood cancer.

The one-time treatment is for aggressive lymphoma in adults.

The Food and Drug Administration approved sales of the therapy from Kite Pharma on Wednesday.

The treatment involves removing immune system cells called T cells from a patient, reprogramming them to target and kill cancer cells and giving them back to the patient. It uses the same technology as the first gene therapy approved in the U.S., Novartis AG’s treatment for childhood leukemia.

Kite became a subsidiary of drugmaker Gilead Sciences this month. Gilead said the therapy will cost $373,000 per patient.


WFLA.com provides commenting to allow for constructive discussion on the stories we cover. In order to comment here, you acknowledge you have read and agreed to our Terms of Service. Commenters who violate these terms, including use of vulgar language or racial slurs, will be banned. Please be respectful of the opinions of others and keep the conversation on topic and civil. If you see an inappropriate comment, please flag it for our moderators to review.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s